Stockhead TV
Got 90 seconds? Then listen to Executive Director, Tom Spurling tell us about their company news.
Nova Eye Medical (ASX:EYE) is introducing a comprehensive portfolio of novel glaucoma treatment options which span the entire disease process – enabling physicians to intervene earlier, and more often, in the treatment of glaucoma.
On March 31st, at the time of recording, the US Food and Drug Administration (FDA) provided 510(k) clearance for the Nova Eye Medical new generation canaloplasty device for canal-based glaucoma surgery.
We gave Tom Spurling from Nova Eye Medical, 90 seconds to tell us more about this recent exciting announcement and why this clearance is so important to the market and for sales.
Have a good idea for our next 90 Seconds With segment? Email us at [email protected].
Health & Biotech
Health & Biotech
Health & Biotech
